Donate

New Data Supports Safety & Efficacy Claims of ALPROLIX

August 17, 2015

Note: This is an edited form of a press release from Biogen. To read the original release in its entirety, click here.  New clinical data support the long-term safety and efficacy of ALPROLIX® [Coagulation Factor IX (Recombinant), Fc Fusion Protein] in people with severe hemophilia B treated for up to two years, Biogen announced on […]

New Data Supports Safety & Efficacy of ELOCTATE

August 11, 2015

Note: This is an edited version of a press release from Biogen. To read the original release, click here. _____________________________________ Newly published clinical data demonstrate that people on extended-interval prophylaxis regimens with ELOCTATE® [Antihemophilic Factor (Recombinant), Fc Fusion Protein] experienced low bleeding rates, Biogen and Swedish Orphan Biovitrum AB (Sobi) announced on Monday, August 10, […]

Baxalta Releases Findings of Potential Extended Half-Life Product

July 21, 2015

Note: This is an edited form of a press release from Baxalta, Inc., originally published on July 16, 2015. To read the full press release, click here. Baxalta Incorporated announced the publication of the complete data from the Phase II/III pivotal study and Phase I trial of BAX 855 in Blood, the journal of the […]


Sign up for E-mails, Dateline Magazine, and other ways to stay connected.